Palmitoyl Tripeptide-8 Neutrazen Factory Supplier Palmitoyl Tripeptide-8 cosmetic peptid

1.Introduction

Retatrutide is a novel multi-target receptor agonist developed by Eli Lilly and Company in the United States, primarily used for the treatment of obesity and type 2 diabetes mellitus. Its core mechanism involves simultaneous activation of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), thereby achieving multi-faceted metabolic regulation.

2.Mechanism of Action

• GLP-1R Activation: Promotes insulin secretion, inhibits glucagon release, lowers blood glucose levels, delays gastric emptying, enhances satiety, and reduces food intake.
• GIPR Activation: Synergizes with GLP-1R to enhance insulin secretion, further improving glycemic control, and modulates appetite through the central nervous system.
• GCGR Activation: Stimulates energy expenditure, increases fat and glycogen breakdown, elevates basal metabolic rate, and reduces body fat storage.
• 
  
• 3.Function
• 
  
• Anti-inflammatory & soothing — Inhibits pro-inflammatory cytokines and reduces skin inflammation
• Sensitive skin care — Soothes irritation caused by UV exposure, mechanical stress, or allergens
• Reduces redness — Alleviates skin redness and discomfort in reactive/sensitive skin
• Neuro-calming — Modulates the neurokinin-1 (substance P) pathway to reduce neurogenic inflammation
• Skin homeostasis — Promotes skin barrier balance and homeostasis
• Skin conditioning agent — Safe for cosmetic use, low irritation risk, non-comedogenic
• 
  

4.Clinical Applications

• Obesity Treatment: In multiple clinical trials, Retatrutide has demonstrated significant weight loss effects. For example, in a Phase 2 trial involving obese patients, the 12 mg dose group achieved 17.5% and 24.2% weight reduction at weeks 24 and 48, respectively, outperforming existing medications.
• Type 2 Diabetes Mellitus Treatment: Retatrutide significantly lowers glycated hemoglobin (HbA1c) levels and improves glycemic control. In type 2 diabetic patients, the 12 mg dose group outperformed 1.5 mg dulaglutide in reducing HbA1c while exhibiting dose-dependent weight loss.
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Preliminary studies indicate that Retatrutide can substantially reduce hepatic fat content and improve liver function markers, offering a novel therapeutic option for non-alcoholic fatty liver disease.